PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. PAION has started to launch remimazolam (Byfavo) in selected European markets. Remimazolam is partnered in multiple territories outside of Europe. Remimazolam is approved in the U.S., the EU/EEA/UK, China and South Korea for procedural sedation and in Japan and South Korea for general anesthesia.
In addition, PAION markets two intensive care products in selected European countries: Angiotensin II (GIAPREZA), a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock, and eravacycline (XERAVA), a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.
Martinstraße 10-12, 52062 Aachen – Germany
|Date||Trading entity / Person||Association||Trade type||Volume|
|27.12.22||Siebert, Gregor||Board||Buy||EUR 24,110.26|
|22.12.22||Dieckow, StB Simone||Close relation||Buy||EUR 500,000.00|
|22.12.22||Fuchs, Anna-Louisa||Close relation||Other||EUR 0.00|
|21.12.22||Zeitfracht GmbH & Co. KGaA||Close relation||Buy||EUR 3,607,500.00|
Oddo BHF Corporates & Markets AGListed Stock Exchange
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.